Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemoradiation in locally advanced HNSCC
NCT05213884Phase 2Completed
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jan 2022
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2022; status: completed.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05213884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213884.